Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response
Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito
Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito
View: Text | PDF
Research Article Hepatology Virology

Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

  • Text
  • PDF
Abstract

Hepatitis delta virus (HDV), a satellite virus of HBV, is regarded as the most severe type of hepatitis virus because of the substantial morbidity and mortality. The IFN system is the first line of defense against viral infections and an essential element of antiviral immunity; however, the role of the hepatic IFN system in controlling HBV-HDV infection remains poorly understood. Herein, we showed that HDV infection of human hepatocytes induced a potent and persistent activation of the IFN system whereas HBV was inert in triggering hepatic antiviral response. Moreover, we demonstrated that HDV-induced constitutive activation of the hepatic IFN system resulted in a potent suppression of HBV while modestly inhibiting HDV. Thus, these pathogens are equipped with distinctive immunogenicity and varying sensitivity to the antiviral effectors of IFN, leading to the establishment of a paradoxical mode of viral interference wherein HDV, the superinfectant, outcompetes HBV, the primary pathogen. Furthermore, our study revealed that HDV-induced constitutive IFN system activation led to a state of IFN refractoriness, rendering therapeutic IFNs ineffective. The present study provides potentially novel insights into the role of the hepatic IFN system in regulating HBV-HDV infection dynamics and its therapeutic implications through elucidating the molecular basis underlying the inefficacy of IFN-based antiviral strategies against HBV-HDV infection.

Authors

Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito

×

Figure 3

HDV superinfection suppresses HBV through the activation of the IFN system.

Options: View larger image (or click on image) Download as PowerPoint
HDV superinfection suppresses HBV through the activation of the IFN syst...
(A) HLCM-HH were first infected with HBV (MOI 50) for 15 days, then superinfected with HDV (5,000 GEq/cell) for indicated durations. The culture supernatants were subjected to the quantification of HBV DNA via RT-qPCR (top, left) or HBeAg (top, right) and HBsAg (bottom, right) with ELISA. Total cellular RNA at each time point was also subjected to the quantification of HBV pgRNA and HDV RNA via RT-qPCR (bottom, left). Results are shown as mean ± SD of triplicate samples. **P < 0.01, ***P < 0.001 were determined by 1-way ANOVA with post hoc Tukey’s test. (B) IFA image of HLCM-HH superinfected with HBV and HDV. Green, HBV Core; red, HDAg; blue, DAPI. Scale bar: 50 μm. The percentage shown in the image indicates the median HBV Core, HDAg, or HBV Core-HDAg dual-positive foci/total number of cells. (C) Cell lysate and culture supernatant of HLCM-HH with either HBV mono-infection or HBV-HDV superinfection were subjected to the assessment of relative expression changes of indicated ISGs via RT-qPCR and the quantification of indicated IFNs via ELISA. Results are shown as mean ± SD of triplicate samples. **P < 0.01, ***P < 0.001 were determined by 1-way ANOVA with post hoc Tukey’s test. (D) HLCM-HH were first infected with HBV (MOI 50) for 15 days followed by superinfection with either mock or HDV in the absence or presence of TOF (10 μM) for 10 days for IFA of indicated molecules. Scale bar: 50 μm. The percentage shown in the image indicates the median HBV Core (top) or HDAg (middle) positive foci/total number of cells. Displayed data represent one of the biological triplicate experiments (A–D).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts